On evidence in support of male circumcision in HIV prevention: What next? [4]

PLoS Medicine

Volumn 3, Issue 1, 2006, Pages 137-138

  Muula, Adamson Sinjani ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF MALAWI   (Malawi)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

CESAREAN SECTION; CIRCUMCISION; CONDOM; COST BENEFIT ANALYSIS; DISEASE TRANSMISSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION PREVENTION; LETTER; SAFE SEX; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; AFRICA SOUTH OF THE SAHARA; HEALTH CARE POLICY; HUMAN IMMUNODEFICIENCY VIRUS 1; INCIDENCE; MALE; METHODOLOGY; NOTE;

AFRICA SOUTH OF THE SAHARA; CIRCUMCISION, MALE; HEALTH POLICY; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MALE; RESEARCH DESIGN;

EID: 32044447234     PISSN: 15491277     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030066     Document Type: Letter

References (1)

1. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, et al. (2005) Randomised, controlled intervention trial of male circumcision for the reduction of HIV infection risk: The ANRS 1265 trial. PLoS Med 2: e298. DOI: 10.1371/journal.pmed.0020298